RYTM — Rhythm Pharmaceuticals, Inc. stock price, charts and financials
QT46Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -3.13 | Insider Own | 1.50% | Shs Outstand | 68.59M | Perf Week | 16.50% |
| Market Cap | 7.93B | Forward P/E | - | EPS next Y | -0.67 | Insider Trans | -6.05% | Shs Float | 55.93M | Perf Month | 0.13% |
| Enterprise Value | 7.87B | PEG | 9.30 | EPS next Q | - | Inst Own | - | Short Float | 17.12% | Perf Quarter | 20.16% |
| Income | -205.43M | P/S | 33.06 | EPS this Y | 3.71% | Inst Trans | - | Short Ratio | 11.97 | Perf Half Y | 11.32% |
| Sales | 239.92M | P/B | 36.50 | EPS next Y | 77.75% | ROA | -46.96% | Short Interest | 9.57M | Perf YTD | 8.03% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -80.48% | 52W High | 122.02 -5.38% | Perf Year | 28.46% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -63.82% | 52W Low | 74.39 55.21% | Perf 3Y | 375.45% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 99.30% - | Gross Margin | 89.00% | Volatility | 5.88% 4.45% | Perf 5Y | 568.77% |
| Dividend TTM | - | EV/Sales | 32.80 | EPS Y/Y TTM | 27.88% | Oper. Margin | -83.62% | ATR (14) | 5.04 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.20 | Sales Y/Y TTM | 66.92% | Profit Margin | -85.59% | RSI (14) | 64.14 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.45 | EPS Q/Q | -2.47% | SMA20 | 8.45% | Beta | 1.95 | Target Price | 144.43 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | 81.82% | SMA50 | 13.46% | Rel Volume | 0.84 | Prev Close | 115.63 |
| Employees | 414 | LT Debt/Eq | 1.71 | Earnings | Nov 03 | SMA200 | 16.78% | Avg Volume | 799.28K | Price | 115.46 |
| IPO Date | Oct 09, 2017 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -0.96% 7.77% | Net Debt/EBITDA | 0.33 | Volume | 672,760 | Change | -0.15% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-05-26 | Reiterated | Canaccord Genuity | Buy | $151 → $154 |
| Aug-05-26 | Reiterated | National Bank | $160 | |
| Jul-07-26 | Reiterated | RBC Capital | Outperform | $145 → $141 |
| Jun-16-26 | Reiterated | Canaccord Genuity | Buy | $143 → $151 |
| Jun-15-26 | Reiterated | Stifel Nicolaus | Buy | $131 → $133 |
| Jun-15-26 | Reiterated | Wells Fargo | Overweight | $143 → $155 |
| May-07-26 | Reiterated | Canaccord Genuity | Buy | $141 → $143 |
| Mar-12-26 | Reiterated | Telsey Advisory | $143 | |
| Mar-12-26 | Reiterated | Wells Fargo | Overweight | $145 → $143 |
| Mar-03-26 | Reiterated | Jefferies | $80 → $125 |
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 239 | 190 | 130 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 26 | 19 | 13 | — | — | — | — | — | — | |
| Gross Profit | 213 | 170 | 117 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 240 | 195 | 144 | — | — | — | — | — | — | |
| Research and Development | 173 | 167 | 238 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -201 | -192 | -266 | — | — | — | — | — | — | |
| Interest Expense | 20 | 21 | 21 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 15 | 17 | 26 | — | — | — | — | — | — | |
| Net Income Before Taxes | -205 | -196 | -260 | — | — | — | — | — | — | |
| Income Taxes | 1 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -206 | -197 | -261 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -206 | -197 | -261 | — | — | — | — | — | — | |
| Net Income | -206 | -197 | -261 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.11 | -3.11 | -4.34 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.11 | -3.11 | -4.34 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.11 | -3.11 | -4.34 | — | — | — | — | — | — | |
| EBITDA | -185 | -174 | -238 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 33.33 | 36.62 | 26.27 | — | — | — | — | — | — | |
| Gross Margin | 89.12 | 89.47 | 90.00 | — | — | — | — | — | — | |
| Operating Margin | -84.10 | -101.05 | -204.62 | — | — | — | — | — | — | |
| Net Margin | -86.19 | -103.68 | -200.77 | — | — | — | — | — | — | |
| Shares Outstanding | 69 | 65 | 61 | — | — | — | — | — | — | |
| Market Capitalization | 7,967 | 6,958 | 3,415 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Garfield Alastair | Chief Scientific Officer | Jul 01 '26 | Option Exercise | 0.00 | 4,445 | 0 | 12,208 | Jul 02 |
| Arbuckle Stuart A | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| JEAN CHRISTOPHE | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| TETRAULT LYNN A. | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| MCGIRR DAVID W J | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| GOOD JENNIFER L | Director | Jun 23 '26 | Option Exercise | 0.00 | 4,712 | 0 | 11,712 | Jun 25 |
| TETRAULT LYNN A. | Director | Jun 22 '26 | Sale | 100.32 | 37,000 | 3,711,896 | 7,000 | Jun 24 |
| TETRAULT LYNN A. | Director | Jun 22 '26 | Option Exercise | 28.27 | 37,000 | 1,045,990 | 44,000 | Jun 24 |
| Smith Hunter C | Chief Financial Officer | May 18 '26 | Option Exercise | 17.87 | 3,000 | 53,610 | 119,611 | May 20 |
| German Christopher Paul | Corporate Controller & CAO | May 15 '26 | Option Exercise | 42.17 | 4,442 | 187,313 | 4,643 | May 19 |
| German Christopher Paul | Corporate Controller & CAO | May 15 '26 | Sale | 92.21 | 4,643 | 428,131 | 0 | May 19 |
| Mazabraud Yann | EVP, Head of International | Apr 01 '26 | Option Exercise | 0.00 | 25,750 | 0 | 66,030 | Apr 03 |
| German Christopher Paul | Corporate Controller & CAO | Mar 04 '26 | Option Exercise | 17.97 | 1,500 | 26,955 | 5,753 | Mar 06 |
| German Christopher Paul | Corporate Controller & CAO | Mar 04 '26 | Sale | 89.56 | 5,614 | 502,790 | 160 | Mar 06 |
| German Christopher Paul | Corporate Controller & CAO | Mar 01 '26 | Option Exercise | 0.00 | 1,162 | 0 | 4,595 | Mar 03 |